2026 Annual Meeting | Industry Therapeutic Update from Novartis Pharmaceuticals: Switch to KESIMPTA® (ofatumumab): Bridging clinical data and real-world experiences with Gabriel Pardo, MD, FAAN and Zenovia, a real patient

Date Tuesday 04/21/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Multiple Sclerosis

Learning Objectives Explore how clinical data and real-world experience inform decision-making around a switch to KESIMPTA.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update from Novartis Pharmaceuticals: Switch to KESIMPTA® (ofatumumab): Bridging clinical data and real-world experiences with Gabriel Pardo, MD, FAAN and Zenovia, a real patient

��ɫ��